Merck’s amyloid-lowering drug, verubecestat, has proceeded to Phase 3 clinical trials after early studies showed it safely lowered the levels…
Articles by Magdalena Kegel
Vaccine development strategies for Alzheimer’s disease should attempt to mirror the natural immunity against toxic amyloid-beta, instead of venturing on…
Alzheimer’s disease starts with neurodegenerative changes in basal brain structures, and spreads to more superficial layers as the disease progresses,…
Abnormalities in the brain’s cellular power plants, known as mitochondria, may drive early Alzheimer’s processes — even before the telltale…
Antibodies extracted from llamas can visualize amyloid-beta plaque and tau deposits in the brains of live animals — a finding that…
Scientists have reported the discovery of a factor capable of lowering levels of tau in the brain. Tau is a protein high…
The mutated gene, as well as the position of the mutation within a gene, impact the kind of symptoms patients…
Patients with inherited forms of Alzheimer’s disease have neurological symptoms other than memory loss, suggesting that physicians need watch for less…
According to a new study, people who have brain deposits of another faulty protein called TDP-43, in addition to amyloid-beta…
Researchers have identified the factor at the end of a molecular chain of events killing nerve cells which have been…